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Allogeneic human tissue-engineered blood vessel
Clay Quint, MD, PhD,a,b Melissa Arief, MD,a Akihito Muto, MD,c Alan Dardik, MD, PhD,c and
Laura E. Niklason, MD, PhD,a,d New Haven, Conn; and Cleveland, Ohio
Background: Arterial bypass graft implantation remains the primary therapy for patients with advanced cardiovascular
disease; however, there is no available synthetic small-diameter vascular graft.
Methods: Tissue-engineered vessels were grown from human smooth muscle cells that were seeded on a biodegradable
scaffold using a biomimetic perfusion system. The human tissue-engineered vessels (hTEV) were decellularized by a
two-step process using a combination of detergents and hypertonic solutions. The mechanical characteristics were
assessed by suture retention strength and burst pressure. The decellularized hTEV were implanted as aortic interposi-
tional grafts in nude rats to evaluate in vivo performance as an arterial graft over a 6-week period.
Results: The human tissue-engineered structure formed a vessel composed of smooth muscle cells and the extracellular matrix
proteins, including collagen. After decellularization, the collagen matrix remained intact while the cellular components were
removed. The mechanical strength of the hTEV after decellularization was similar to human vein in vitro, with a burst pressure of
1,567 384mmHg (n 3) versus 1,680 307mmHg for human saphenous vein. The hTEVs had a high patency rate (four of
five grafts) without evidence of rupture or aneurysm over a 6-week period as an aortic interpositional graft in a nude rat model.
Histologic analysis showed a thin neointimawith a confluent endothelium and a subendothelial layer of smoothmuscle cells on the
explanted tissue-engineered vessels.Transmission electronmicroscopyon the explanted tissuedemonstrated elastin formation in the
neointima and intact residual collagen fibers from the tissue-engineered vessel.
Conclusions:ThehTEVhadahighpatency rate andremainedmechanically stable as anaortic interpositionalgraft in anude rat.The
vessel supported the growth of a neointima with endothelial cells and smooth muscle cells. The host remodeling suggested the
engineered matrix had a positive effect to create a regenerated vascular graft. (J Vasc Surg 2012;55:790-8.)
Clinical Relevance: The demand for alternative arterial conduits is due to the poor clinical efficacy of existing synthetic
grafts for small-diameter artery applications, with many patients lacking adequate saphenous vein. We showed that a
vessel culture system could produce a human vascular graft that could function as an arterial conduit in a small-diameter
animal model. The decellularization process for the human tissue-engineered vessels expands the clinical potential by
generating an allogeneic graft that is readily available for implantation.
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0Tissue engineering technology has the potential to gen-
erate engineered arterial grafts for multiple cardiovascular
applications.1 Engineered vessels for arterial conduits have
been developed that have similar structural and functional
properties as native vessels.2,3 There are multiple approaches
to biologic-based grafts that have been implanted in animal
models.2,4-7 Examples of these techniques include collagen
gel structures, decellularized native vessels, cell sheets to form
a tubular structure, and synthetic biopolymers.2,4-7 Several of
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Despite successful proof of concept for tissue-engi-
eered vessels in animal models, significant limitations exist
hat could prevent the widespread clinical implementation
f completely autologous engineered arteries. Specifically,
ged human smooth muscles produce vessels that have
oor mechanical properties when used in vascular tissue
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Volume 55, Number 3 Quint et al 791engineering.8 Alternative strategies such as using human
telomerase reverse transcriptase (hTERT)-infected aged
cells or using a bone-marrow progenitor cell as the primary
cell source also failed to produce a vessel with mechanics
suitable for arterial implantation.8,9
Allogeneic tissues have been used for replacement tissues
for cardiovascular therapies.10,11,12 Decellularized native ves-
sels sustain mechanical properties as arterial bypass grafts, and
have less immunologic response as compared to cryopreserved
tissue.12,13 Engineered vessels have already been shown to
retain their mechanical integrity after decellularization using
animal cells.14 The advantages, including a decellularization
step to produce an allogenic graft, are a reduced lead time and
the opportunity to use a “younger” cell source to produce the
mechanically robust matrix of the vessel wall. Using banked,
nonautologous cells to produce engineered tissues would
improve tissue consistency and the ability to screen banked
cells for infectious contamination.14 Similar to synthetic
grafts, the decellularized engineered graft would be available
for immediate use.
In this study, we report the in vitro and in vivo properties
of a decellularized tissue-engineered vessel (TEV) made from
human vascular smooth muscle cells. This study characterizes
the histologic and biomechanical properties of the human
tissue-engineered vessel (hTEV) before and after decellular-
ization, which are shown to be similar to native human vessels.
We hypothesize that a completely TEV derived from human
vascular smooth muscle cells can demonstrate suitable prop-
erties for implantation in vitro, and then remain mechanically
stable in a rat aortic model over 6 weeks.
METHODS
Isolation of human smooth muscle cells and vessel
culture. Human aortae from near the aortic arch were
obtained from human transplant donors during organ har-
vest. The medial layer of the aorta was isolated using sterile
instruments. The isolated media layer was then sectioned
into pieces approximately 0.3 cm by 0.3 cm and placed
lumen-side down in T75 falcon flasks coated in 1% bovine
gelatin with M199 plus 20% bovine serum and 1% penicil-
lin/streptomycin as media. The tissue was cultured in an
incubator to allow the smooth muscle cells to migrate onto
the flasks, and the media was changed every 3 days. After 2
to 3 weeks, smooth muscle cells reached confluency.
Poly-glycolic acid (PGA) mesh (Concordia, Mansfield,
Mass) was sutured over a 1-mm diameter silicone tube
(Saint Gobain, Valley Forge, Pa) using uncoated Dexon
suture (Syneture, Mansfield, Mass). The silicone tubing
and bioreactor equipment were sterilized and set up as
previously described.2,3 The PGA mesh was sutured
around the silicone tubing, and the silicone tubing was
threaded through the side-arms of the bioreactor. A sus-
pension of media containing 4.5 million human smooth
muscle cells at passage 3 was seeded onto each of the PGA
mesh tubes. The culture medium was Dulbecco’s modified
Eagle’s medium (DMEM; Gibco, Carlsbad, Calif) supple-
mented with 15% fetal bovine serum (Hyclone, Logan,
Utah), 5% human serum (Gemini Bio-Products, Sacra- iento, Calif) 2.6 mg/mL HEPES (N-(2-Hydroxyethyl-
piperazine-N=-(2-ethanesulfonic acid); Sigma, St. Louis,
o), 50 g/mL proline (Sigma), 20 g/mL alanine
Sigma), 50 g/mL glycine (Sigma), 3 ng/mL CuSO4
Sigma), 10 ng/mL basic fibroblast growth factor (R&D,
inneapolis, Minn), and 10 ng/mL platelet-derived
rowth factor-bb (R&D). Cultures were allowed to prog-
ess for 10 weeks with media changes every 5 days and
itamin C injections every 3 days.3
Decellularization of engineered vessel. The TEV
ere first treated in a solution containing 8 mM CHAPS
3-[(3-Cholamidopropyl)dimethylammonio]-1-propane-
ulfonate; Sigma), 1 M NaCl (Sigma), and 25 mM EDTA
Boston Bioproducts, Ashland, Mass) in phosphate-buff-
red saline (PBS; Gibco) for 1 hour on a stir plate at 37°C
hen washed three times in PBS for 10 minutes. The vessels
ere then treated with a second buffer containing 1.8 mM
odium dodecyl sulfate (Sigma), 1 M NaCl, and 25 mM
DTA in PBS for 1 hour on a stir plate at 37°C and washed
hree times in PBS. Vessels were treated overnight with
BM2 (without hydrocortisone; Lonza, Basel, Switzer-
and) with 12% fetal bovine serum and then stored in PBS
ith 1% penicillin streptomycin at 4°C.15
Vessel characterization. Intraluminal pressure was
easured by attaching the vessel to a flow-loop system, and
ydrostatic pressure was increased at a rate of approxi-
ately 50 mm Hg/sec until failure. Pressure was digitally
ecorded. Suture retention was measured by a single throw
f 6-0 prolene suture (3.5  0.3 mm bite) through the
EV, and then weights were sequentially added (in 5-gram
ncrements). The weight at failure was recorded.2
Collagen was quantified by measuring hydroxyproline
evels as previously described. A 1:10 w/w ratio of hydroxy-
roline and collagen was used to calculate the collagen
ontent of the vessels. The collagen content was calculated
s the percentage of dry weight.2
DNA contents of fresh and decellularized vessels
ere determined fluorometrically, as previously de-
cribed. Tissue was digested in papain solution under
igh temperature (60°C for 24) and low pH conditions
for 24 hours), and PicoGreen (Invitrogen, Carlsbad,
alif) was added to the digest, causing the DNA fluores-
ence at an excitation wavelength of 485 nm and an
mission wavelength of 535 nm.14
Histomorphological analysis included intima to media
atios for the native aorta compared with residual engi-
eered vessel to neointima ratio. Using elastin stain (EVG),
he area of the intima and media of the native aorta were
alculated; in a similar fashion, the area of the residual
ngineered matrix and neointima were obtained.
Graft implantation. Six female nude rats (Crl: NIH-
oxn1rnu; Charles River Laboratories, Wilmington, Mass)
0- to 12-weeks old were anesthetized with intraperitoneal
njections of ketamine (100 mg/kg) and xylazine (10 mg/
g). The abdominal hair was clipped, and the abdomen was
repared with Betadine and alcohol. A midline laparatomy
ncision was made, and the abdominal viscera were lateral-
zed for exposure of the abdominal aorta. An 18 dissect-
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March 2012792 Quint et aling scope (Zeiss, Thornwood, NY) was used to dissect the
abdominal aorta surrounding tissue. Proximal control was
at the position of the infra-renal aorta, and distal control
was superior to the aortic bifurcation. A 5-mm long, 1-mm
diameter tissue-engineered graft was sutured as an inter-
postional end-to-end anastomosis with 10-0 monofilament
nylon sutures using simple interrupted stitches. The prox-
imal and distal clamps were removed, and flow was restored
through the graft. Hemostasis was achieved prior to clo-
sure, and the abdomen was sutured with a running 5-0
prolene stitch. Animals recovered on warmed pads and
were monitored for hind limb paralysis before returning to
their preoperative cages. Postoperatively, the rats were
treated with plavix (25 mg/kg) four times per week. This
protocol was approved by the Institutional Animal Care
and Use Committee of Yale University in compliance with
animal care and handling with the Guide for the Care and
Use of Laboratory Animals published by National Institute
of Health.
In vivo ultrasound and microcomputed tomography.
Rats were anesthetized with intraperitoneal injections of
ketamine (100 mg/kg) and xylazine (10 mg/kg). The
grafts were evaluated along a longitudinal axis via transab-
dominal ultrasonography using the Vevo 770 ultrasound
machine (VisualSonics, Toronto, Ontario). Lumens of the
grafts were evaluated to assess for graft patency, stenosis/
occlusion, or aneurismal dilation. One graft was also eval-
uated by high-resolution (50 m) microcomputed tomog-
raphy (micro-CT) imaging (Scanco Medical MicroCT 40,
Southeastern, Pa). The rats were anesthetized at the time of
sacrifice, and a thoracotomy incision was made. The tho-
racic aorta was cannulated for the administration of a bolus
of contrast (Omnipaque; Amersham Biosciences, Piscat-
away, NJ). The residual TEV was highlighted using cross
section images to determine when there was a transition
from native aorta to engineered vessel.
Explant characterization. Grafts were explanted at 6
weeks by perfusion fixation and were analyzed by histology,
immunohistology, and transmission electron microscopy.
For histology and immunohistology, the explanted grafts
were harvested and placed in 10% formalin (Sigma) over-
night. The grafts were rinsed with PBS and paraffin embed-
ded. The graft lumen and graft thickness were evaluated
with hematoxylin and eosin (H&E) staining quantified by
using ImageJ software (Image Processing and Analysis in
Java; National Institute of Health, Bethesda, Md). Immu-
nohistological staining included trichrome to assess colla-
gen and elastic Van Gieson for elastin. Additional immu-
nohistochemical staining was performed for smoothmuscle
cell -actin (Dako, Carpinteria, Calif) to assess smooth
muscle cell ingrowth and von Willebrand factor (Dako) for
endothelial cell migration using a streptavidin-biotinylated
peroxidase kit (Vector 6101 or 6102; Vector Labs, Burlin-
game, Calif). Using H&E staining, hoop stress was calcu-
lated for the explanted tissue engineered vessels and com-
pared with the native aorta (  Pressure * radius/
thickness). oVessel segments were fixed for transmission electron
icroscopy (TEM) in 4% glutaraldehyde (EMDChemicals
nc, Gibbstown, NJ) and 0.1 M sodium cacodylate trihy-
rate (Sigma). Fixed vessel segments were thin-sectioned
nto cross sections. A FEI Tenai Biotwin 80- to 120-kV
ransmission electron microscope was used to view the
lide.
Statistical analysis. All quantitative results were ob-
ained from three different cultivated vessels. Since the
ame vessels were used before and after decellularization, a
aired t test was used for analysis. The data was expressed as
he mean  SEM. Statistical analysis was performed using
tatview 6.0. A value of P  0.05 was considered to be
tatistically significant.
ESULTS
Vessel morphology. The TEV had a similar structure
o a native artery. The hTEV had a tubular form after the
ulture period of 10 weeks under pulsatile conditions (Fig
, A). The PGA scaffold rapidly degraded into nontoxic
roducts, and allowed smooth muscle cells to migrate
hrough the scaffold to form a tubular structure.16 On
istology, smooth muscle cells distributed throughout the
essel wall (Fig 1, B). The wall thickness was on the same
agnitude of a human saphenous vein at 300 to 400 m.
The decellularized TEV demonstrated stability of the
xtracellular matrix, while the cellular components were
fficiently removed. On histology, the H&E staining
howed the overall vessel structure intact after decellular-
zation withminimal degradation of the extracellular matrix
Fig 1, C and D). After decellularization, there was a slight
ncrease in diameter of the vessel because of a loss of muscle
one. The Masson’s Trichrome stain for collagen appeared
imilar before and after decellularization (Fig 1, E and F),
herein all the blue color was collagen matrix. Note that
he PGA polymer fragments, visible as circles in the images,
onspecifically absorb the blue stain. The histologic find-
ngs were confirmed by quantitative evaluation of collagen
nd DNA content. There was no significant change in
ollagen content in the TEV after decellularization (Table;
 3, P  .47). The fractional collagen content actually
ncreased slightly and has been attributed to the loss of cells
nd other proteins in the decellularized group. The re-
oval of cellular components was shown by a loss of nuclei
n the H&E stain after decellularization, and verified by a
ignificant decrease in DNA content as a percentage of dry
eight after decellularization (Table; n  3, P  .0014).
ence, the decellularization treatment of hTEV preserves
he collagen matrix, yet removes cellular material.
Vessel mechanics. The mechanical properties of the
TEV are comparable to fresh tissues. The mechanical
roperties evaluated included suture strength for handling
haracteristics and burst pressure to assess vessel strength
Table). The suture strength was minimally reduced after
ecellularization (Table; n  3, P  .0572). Although the
uture strength of the engineered vessel was somewhat low,
he vessels could be anastomosed to the native aorta with-
ut anastomotic bleeding or tearing at the suture line.2 As
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carotid artery has a suture retention of 300  9 grams. We
measured burst pressure of the engineered vessels by in-
creasing intraluminal pressure until the vessel failed at its
weakest point. The hTEV had a nonsignificant reduction in
burst pressure after decellularization (Table; n  3, P 
.41). Even after decellularization, the burst pressure of
Fig 1. Human tissue-engineered vessel (hTEV). A, Gro
scale  500 m. C, Higher magnification H&E of h
scale 100m.E,HumanTEV,Masson’s Trichrome fo
Trichrome for collage, scale  100 m.
Table. Properties of fresh and decellularized human tissue
Fresh eng
Collagen content (% per dry wt) 31  7
DNA content (% per dry wt) 0.52  0
Suture retention strength (grams) 47  6
Burst pressure (mm Hg) 1722  51567 384 mmHg (n 3) was similar to reported values lor saphenous vein (1680 307mmHg).17 Therefore, the
echanical properties of the human tissue-engineered ar-
eries were judged to be suitable for implantation.
Implantation study. An animal model was used to
valuate the in vivo performance of the hTEV. A nude rat
odel was used to limit the adaptive immune-rejection
esponse; however, the innate immune response that regu-
ture of 1-mm hTEV. B, Cross section of hTEV, H&E,
scale  100 m. D, Decellularized H&E of hTEV,
gen, scale 100m. F,Decellularized hTEV,Masson’s
ineered vessels
ed vessel Decellularized engineered vessel
3) 36  8 (n  3; P  .47)
(n  3) 0.05  0.013 (n  3; P  .0014)
3) 40  8 (n  3; P  .057)
 3) 1567  384 (n  3; P  .41)ss pic
TEV,
r colla-eng
ineer
(n 
.030
(n ates inflammation was intact in these animals. An ideal
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March 2012794 Quint et allocation for implantation to match the graft diameter (1
mm) was an interpositional abdominal graft (Fig 2,A). The
overall patency rate at 6 weeks in this study was 83% (n 
6). The grafts were evaluated for patency at 2 weeks by
ultrasound (Fig 2, C), and one graft had occluded that
suggested a technical failure at the time of implantation.
The ultrasound at 2 weeks in the patent grafts did not
Fig 2. Implantation and in vivo imaging. A, Implanta
(hTEV) (arrows at the proximal and distal anastomosis).
at the time at sacrifice at 6 weeks with patent decellularize
decellularized hTEV at 2 weeks (brackets represent the bsuggest any significant dilation. At the time of sacrifice, one rnimal underwent micro-CT that demonstrated a widely
atent graft without evidence of dilatation or aneurysm
ormation (Fig 2, B). The in vivo imaging results regarding
atency correlated to explant histology.
Explanted grafts. The explanted grafts by histology
howed a high patency rate, no evidence of graft dilatation,
nd neotissue formation. By H&E (Fig 3, A), the imaging
f 1 mm decellularized human tissue-engineered vessel
vivo micro-computed tomography (micro-CT) imaging
EV (color highlight is the graft). C, In vivo ultrasound of
s of the graft).tion o
B, In
d hTesults were confirmed with a patency rate of 83% (n  5)
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Volume 55, Number 3 Quint et al 795by histology. The explanted grafts were negative for evi-
dence of graft dilation, with relatively uniform graft wall
architecture. Although there was no significant dilation
within each segment of the explanted vessels, only one time
point at 6 weeks was obtained for histology. The decellu-
larized human tissue-engineered graft exhibited neotissue
integration on the luminal and outer side of the matrix.
Host cells did not completely infiltrate through the entire
wall of the graft, and there was a remaining acellular layer at
6 weeks (Fig 3, A). The one occluded vessel was likely
related to technical failure with acute or delayed thrombosis
that resulted in occlusion. The small size of the implanted
graft into the rat aorta was a technically challenging proce-
dure, and during the implantation the graft could have
become narrowed related to suturing.
Histomorphology was used to determine the intimal area
to the medial area and to obtain hoop stress. The intima-to-
media ratio for native aorta was 0.14 0.02, compared with
the residual-engineered matrix-to-neointima ratio for the
tissue-engineered vessel of 0.61  0.14. The intima on the
native aorta was a thin layer, and there was a more substan-
tial neointima that was formed on the decellularized engi-
neered vessel. Using the H&E slides for the tissue-engi-
neered vessels at explants and adjacent native aorta as a
reference, the hoop stress was 48,200 5500 Pa compared
with native aorta hoop stress of 77,000  9100 Pa. The
hoop stress of the TEV was less than the native aorta
because, during the remodeling process, the engineered
vessel has a greater thickness as compared with the native
Fig 3. Explant immunohistochemistry of decellularized
with (A) H&E, (B) smooth muscle -actin, (C) von Wi
m.aorta. wThe neotissue investing and adjacent to the grafts was
haracterized by immunohistochemistry for smooth mus-
le and endothelial cell markers. The cells on the outer side
f the engineered vessels were predominately positive for
mooth muscle -actin (Fig 3, B), indicating a smooth
uscle or myofibroblast phenotype. The neointima also
ad a thin layer of smooth muscle cells. The luminal surface
isplayed a confluent lining of endothelial cells on all
amples, which were positive for vonWillebrand factor (Fig
, C). As an internal control for the endothelial staining on
he engineered vessels, the same degree of endothelial
taining was observed in the small vessels in the periphery of
he adventitia. Since the decellularized TEV was acellular at
he time of implantation, the endothelial cells were host
erived. The TEM also showed flat cells on the luminal
urface of the explanted graft that was consistent with
ndothelial cells. The endothelialized neointima likely
ided in preventing graft thrombosis and was thin and did
ot lead to narrowing of the lumen.
The decellularized hTEV provided a matrix that sup-
orted the host cellular infiltration and stimulated a func-
ional neointima. Elastin formation within the neointima
as shown on elastic van Gieson staining (Fig 3, D). The
resence of elastin was confirmed by ultrastructural analysis
sing TEM. The characteristic dense elastin fibers were
etected by TEM (Fig 4, A). The elastin fibers were seen
djacent to the smooth muscle cells in the neointima. The
ollagen fibers found in the acellular layer derived from the
ecellularized TEV remained intact after explanation at 6
an tissue-engineered vessel (hTEV) at 6 weeks stained
nd factor, and (D) elastin Van Gieson. Scale bar  100hum
llebraeeks (Fig 4, B). The cellular ingrowth is demonstrated by
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March 2012796 Quint et althe host rat through histology and immunohistochemistry
as compared with the acellular engineered vessel at the time
of implantation.
DISCUSSION
TEV may provide an alternative conduit over currently
available synthetic grafts. A biologic-based structure that is
decellularized could be tailored to a range of lengths and
diameters, widely available, and easily transported. There
are only two tissue-engineered blood vessels that are cur-
rently under clinical investigation, and both methods have
shown promising results in early clinical trials.18,19 Only
one method has been used for arterial conduits, and the
process to generate a living engineered vessel takes 7 to 9
months.19 Although the use of autologous tissue is a the-
oretic ideal, the complexity and lead time required to
develop individualized grafts will likely constrain com-
pletely autologous tissue-engineered vessels for therapeutic
applications.
The immunodeficient rat model provided an appropri-
ate model for mechanical evaluation of hTEV. The in vitro
mechanical properties suggested the grafts were suitable for
implantation, and the rat implantation study confirmed the
mechanical stability of the vessels. The imaging and histol-
ogy did not indicate the decellularized hTEV had dilation
or stenosis after 6 weeks as an aortic interpositional graft.
The graft appeared to stimulate remodeling, with the pres-
ence of smoothmuscle cells and a luminal confluent layer of
endothelial cells. Since collagen can be thrombogenic, an-
tiplatelet therapy with plavix was given to the rats over the
6-week period to prevent thrombosis. An endothelial layer
was present on the grafts after 6 weeks, and likely the
antiplatelet therapy could have been discontinued at this
time.
The integration of decellularization and tissue engi-
neering concepts to form an allogeneic matrix could ex-
pand the therapeutic indications for these grafts. The only
option to engineer vessels with cells intact would be to use
autologous smooth muscle cells; however, the aged
Fig 4. Transmission electron microscopy of explanted
weeks. A, The luminal surface coated with endothelial c
layer adjacent to smooth muscle cells. Scale bar 10 m
ing collagen fibers. Scale bar  500 nm.smooth muscle cells produced vessels with poor mechanics dot suitable for implantation.8 The mechanism leading to
oor vessel mechanics was an inverse relationship to donor
ge and the cellular factors of proliferative capacity and
ollagen production. Allogenic grafts are preferable to xe-
ogenic grafts because of the presence of xenogeneic anti-
ens, such as the Gal epitope, which can lead to failure as a
esult of biodegeneration and calcification.20 Allogeneic
rafts can be processed with various treatments that lead to
ifferent mechanical and immunologic responses. Cryo-
reservation was an early approach as a clinical peripheral
ypass graft, although it has been shown to have low
atency rates and to stimulate an immunogenic re-
ponse.10,21 Glutaraldehyde-fixed cardiovascular tissue has
een utilizedmostly in cardiac valves, but this approach also
eads to late failures from inflammation and eventual calci-
cation.22,23 Decellularization with enzymatic or deter-
ents methods maintain mechanical properties of a native
rtery as a conduit, but has less immunologic response
hen compared with cryopreservation.12,13 The advantage
f using a decellularized TEV is that the majority of the
mmune response-generation is due to the cellular compo-
ents, while the majority of the mechanical stability is from
he extracellular matrix.14 The decellularized TEV may
rovide a model for clinical use of tissue-engineered prod-
cts.
There is no ideal animal model to test how vascular
rafts will perform in humans; each animal model has an
ssociated set of limitations.24 None of the larger animal
odels offer an immunodeficient species, and rat implants
re technically more feasible that mouse implants. The only
nimal models to test hTEV that will not generate a xeno-
enic inflammatory response are a nude mouse/rat model
r an old world primate model. Although a nude rat model
Crl: NIH-Foxn1rnu) is immunocompromised, the rats are
nly T-cell deficient with an intact B-cell response and
ntact innate immune system. This is in contrast to a severe
ombined immunodeficiency mouse, for instance, that is
-cell and B-cell deficient. In addition to a hTEV, our
aboratory has recently published a porcine TEV that was
llularized human tissue-engineered vessel (hTEV) at 6
arrowhead) and elastin fibers (arrow) in the neointimal
he accellular remnant decellularized hTEV demonstrat-dece
ells (
. B, Tecellularized and implanted into a porcine carotid model
R1
1
1
1
1
1
1
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1
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sponse.25 A dog or large animal model is not an ideal
animal model for testing hTEV because a xenogenic im-
mune response will contribute to the inflammatory re-
sponse.26 Immunosuppressive medication could be used
for a human vessel as a xenogenic implant, but this intro-
duces other confounding factors. The only large animal
model would be an old word primate, which is very expen-
sive and presents ethical issues. Although limited, the nude
rat/mouse models are the best models for preliminary
evaluation of hTEV for in vivo graft implantation.
The primary drawbacks of a rat model are the high
patency rates for short aortic interpositional grafts, despite
the small diameter of the graft.24 The majority of prior
interpositional aortic implants in the rat aorta are polytet-
rafluoroethylene or polyurethane; polytetrafluoroethylene
grafts are associated with very high patency and endotheli-
alization rates.27,28,29 Rat aorta studies have provided use-
ful data on the assessment of cellular integration of syn-
thetic polymer structures or TEV, although the patency
rates are also very high.28,29
The limitations to this study include a small sample size
and need for longer-term follow up. The patent grafts all
had a similar appearance, with a widely patent lumen, and
more animals would be expected tomaintain a high patency
rate. Longer-term results – up to 1 year – are needed to
further understand the potential for late aneurismal forma-
tions or pathologic neointima that could cause stenosis.
Since the response to implantation of other synthetic grafts
has been well described, this study did not include other
interpositional aortic grafts as a comparison. A control graft
could have been a cellular engineered vessel, which has
been implanted into other animal models, except this vessel
would induce an inflammatory response in the rat model.
CONCLUSIONS
hTEV may provide an alternative option for small-
diameter vascular grafts. Despite its limitations, the aortic
implant in the nude rat can provide a screening tool to
assess arterial graft performance and insight to the remod-
eling process.
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and coaxial subendothelial SMCs. This is a remarkable and
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The poor availability of usable autogenous conduit for
vascular bypass grafting remains a significant clinical problem.
Less than half of all patients requiring lower extremity bypass
grafting can be reconstructed using appropriately sized, disease-
free, single-segment greater saphenous vein. This has long
prompted the search for an operative strategy wherein, instead
of harvesting autologous veins or implanting prosthetics, use-
able vascular conduits can be “grown” in a laboratory in the days
prior to elective revascularization. Such “tissue-engineered”
conduits are the subject of the study conducted by Quint et al
and reported herein.
In a series of bench top and animal experiments, human
tissue engineered vessels (hTEV) were grown using a process
employing human aortic smooth muscle cells (SMCs), biode-
gradable scaffolds, biomimetic perfusion, and decellularization.
After creation in vitro, the hTEVs were implanted as aortic
interposition grafts in nude rats and found to have acceptable
6-week patency (83%) without evidence of aneurysm formation
or rupture. When explanted and examined, the decellularized
hTEVs were found to have recruited a confluent endotheliumOf course, a myriad of issues must be addressed prior to
onsideration of clinical application of hTEVs. First and foremost
s the certain immunogenicity of conduits created using heterolo-
ous human tissue, immunogenicity that was not observed in this
xperiment given the use of nude hosts. Decellularization could be
xpected to attenuate immunologic responses to the level of toler-
nce, perhaps, but even low levels of chronic antigenicity may
egatively affect patency. The logistical practicalities of the ap-
roach also loom large, as the consistent creation of acceptable
onduits is obviously a highly specialized and technical endeavor.
o we really envision a time when personalized surgical “spare
arts” are routinely available in clinical practice? It seems more
ikely that conduits such as these will be created in a central,
ommercial laboratory and distributed to hospitals in a similar
ashion as currently available medical devices. Thus, the “personal”
ature of such devices will likely be limited.
These shortcomings notwithstanding, Quint and colleagues
ffer a provocative and inventive solution to the ubiquitous prob-
em of small-diameter, long-segment vascular conduit availability.
t is hoped that this group will refine their process and technique,
xtend these initial experimental observations, and swiftly advance
o the clinical phase of development.
